The central claim of the article, titled Metabolism licenses the senescence secretome, is that metabolic state functions as a gatekeeper determining which inflammatory and growth-promoting signals a senescent cell actually produces. In other words, two cells can be equally senescent by the classical criteria, showing stalled cell cycles, enlarged morphology and markers such as senescence-associated beta-galactosidase, yet produce dramatically different secretomes depending on how their metabolic machinery is configured. This reframing has significant consequences, because it suggests that targeting metabolism could offer a way to silence the harmful secretions of senescent cells without necessarily eliminating the cells themselves.

To understand why this idea matters, it helps to review what the senescence secretome actually contains. Depending on the cell type and the trigger, senescent cells can secrete pro-inflammatory cytokines such as interleukin-6 and interleukin-8, chemokines that recruit immune cells, matrix-remodeling enzymes including matrix metalloproteinases, growth factors that can drive neighboring cells to proliferate, and a variety of lipid mediators and extracellular vesicles carrying proteins and nucleic acids. In the short term, this signaling can be beneficial. It alerts the immune system to a potentially dangerous cell, promotes wound healing and contributes to tissue repair after injury. The problems arise when senescent cells accumulate with age or in diseased tissue, because their chronic secretory output then becomes a persistent source of low-grade inflammation, a phenomenon often described as inflammaging.

The traditional view of how the secretome is controlled has centered on DNA damage signaling. When cells experience telomere shortening, oxidative stress, oncogene activation or genotoxic drugs, they activate pathways involving the ATM and ATR kinases, which in turn engage the p53 and p21 axis and the p16INK4a and retinoblastoma pathway. These cascades enforce the cell-cycle arrest, and through the transcription factors NF-kappaB and C/EBP beta they also drive expression of many secreted factors. This DNA damage-centered model explains a great deal, but it leaves an important observation unexplained: the secretome varies enormously between contexts, and the same senescence trigger can produce very different inflammatory outputs in different metabolic environments.

The Cell Research perspective proposes that metabolism supplies the missing layer of regulation. Senescent cells undergo profound metabolic rewiring. They frequently display increased glycolysis, elevated mitochondrial oxidative phosphorylation, altered autophagic flux, changes in lipid metabolism and, in many cases, a shift toward biosynthetic programs that support their survival despite being unable to divide. Mitochondrial dysfunction is a particularly well-documented feature, and mitochondria that lose their integrity can release mitochondrial DNA and other damage-associated molecular patterns that amplify inflammatory signaling through innate immune sensors such as cGAS and Toll-like receptors. In this way, the metabolic state of the cell directly feeds the signaling circuits that assemble the secretome.

Several specific metabolic nodes illustrate the principle. The mevalonate pathway, best known for producing cholesterol, also generates isoprenoid intermediates required for the prenylation of small GTPases, and inhibition of this pathway with statins has been shown in multiple studies to blunt the secretion of inflammatory cytokines by senescent cells. Prostaglandin metabolism is another critical branch: the enzyme COX-2 and its downstream prostaglandin E2 production have been linked to the maintenance of the senescence program itself, and interfering with prostaglandin signaling can weaken both senescence and its secretory output. NAD metabolism, sirtuin activity, acetyl-CoA availability and histone acetylation states all influence how accessible the genes encoding secreted factors are to the transcriptional machinery. Even the availability of glucose and amino acids can shift the balance between a restrained and a fully inflammatory secretory phenotype.

This metabolic licensing concept also helps explain one of the most puzzling features of senescence biology: its heterogeneity. Single-cell analyses have revealed that senescent cells in the same tissue can express strikingly different sets of secreted factors, and that this diversity changes with age, tissue type and disease context. If the secretome were determined solely by the DNA damage response, one might expect more uniformity. But if the secretome is licensed by metabolism, then the local nutrient environment, oxygen tension, mitochondrial health and lipid availability of each cell would naturally produce a spectrum of secretory states. This heterogeneity is not noise; it is a direct readout of each cell’s metabolic circumstances, and it may explain why senescent cells can be reparative in one setting and destructive in another.

The therapeutic implications are considerable. Over the past decade, a class of drugs called senolytics has been developed to selectively kill senescent cells, and early clinical trials have reported encouraging results in conditions ranging from idiopathic pulmonary fibrosis to diabetic kidney disease. But clearing senescent cells entirely may not always be desirable, given their documented roles in wound healing, tissue regeneration and tumor suppression. An alternative strategy, sometimes called senomorphics, aims to reprogram senescent cells so that they retain their growth arrest and tumor-suppressive functions while losing their inflammatory secretions. The metabolic licensing framework provides a conceptual foundation for this approach: if metabolism licenses the secretome, then metabolic interventions, whether through statins, NAD-boosting compounds, mitochondrial modulators or dietary strategies, could in principle dial down the harmful components of the secretome while leaving the protective aspects of senescence intact.

The perspective also raises important questions for future research. Which metabolic enzymes are the critical licensing factors in vivo, and do they differ between tissues? How reversible is metabolic licensing, and can a senescent cell whose secretome has been silenced by metabolic intervention be pushed back into a benign state permanently, or only transiently? How do systemic factors such as diet, exercise and obesity, all of which reshape whole-body metabolism, modulate the secretory behavior of the senescent cells distributed throughout our tissues? And how do the metabolic states of senescent cells interact with the immune system, which must constantly decide whether to clear, tolerate or be activated by these cells? Answering these questions will require integrating metabolomics, single-cell transcriptomics and functional assays in physiologically relevant models, an effort the authors argue should now be a priority for the field.

What emerges from this analysis is a view of the senescent cell as a metabolically governed signaling hub rather than a passive casualty of damage. The DNA damage response may initiate senescence, but metabolism determines the character and intensity of the message the cell broadcasts to its neighbors. As the global population ages and age-related diseases place growing demands on health systems, the ability to modulate, rather than merely eliminate, senescent cells could become a cornerstone of geriatric medicine. The idea that metabolism licenses the senescence secretome offers both a unifying explanation for the heterogeneity that has long frustrated researchers and a practical roadmap for interventions that could preserve the benefits of cellular senescence while curbing its inflammatory costs. It is a reminder that in biology, as in economics, what a cell says depends heavily on the resources it has to spend.

Subject of Research: Metabolic regulation of the senescence-associated secretory phenotype in aging and disease

Article Title: Metabolism licenses the senescence secretome

Article References: Picallos Rabina, P., & Demaria, M. (2026). Metabolism licenses the senescence secretome. Cell Research. https://doi.org/10.1038/s41422-026-01295-9

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01295-9

Keywords: cellular senescence, senescence secretome, metabolism, inflammaging, mitochondrial dysfunction, senolytics, senomorphics, DNA damage response, aging, cytokines, NAD metabolism, Cell Research

At its core, NAD⁺ serves as a quintessential electron carrier, shuttling electrons during metabolic reactions to sustain ATP production. However, its functions transcend mere redox chemistry. NAD⁺ is also a substrate for a collection of NAD⁺-dependent enzymes, including sirtuins, poly(ADP-ribose) polymerases (PARPs), and cyclic ADP-ribose synthases, which participate in regulating gene expression, DNA repair, and calcium signaling. These multifaceted roles position NAD⁺ as a lynchpin in maintaining cellular homeostasis, responding dynamically to physiological cues and stress.

Integral to the regulation of intracellular NAD⁺ levels is the nicotinamide phosphoribosyltransferase (NAMPT)-mediated salvage pathway. NAMPT catalyzes the conversion of nicotinamide (NAM), a byproduct of NAD⁺ consumption, back into nicotinamide mononucleotide (NMN), a direct NAD⁺ precursor. This salvage pathway not only ensures the replenishment of NAD⁺ pools but also intricately controls its availability to meet fluctuating cellular demands. Disruptions in NAMPT activity have been strongly correlated with pathological conditions, emphasizing the enzyme’s significance in human health and disease.

A decline in NAD⁺ levels is a well-documented hallmark of aging and a variety of stress-related states. This reduction compromises mitochondrial function, leads to the accumulation of DNA damage, and impairs metabolic flexibility, cumulatively destabilizing cellular homeostasis. These findings have instigated fervent exploration into therapeutic approaches centered on restoring or augmenting NAD⁺ concentrations as a means to combat age-associated decline and pathological disorders.

Supplementation with NAD⁺ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) has garnered significant attention, fueled by preclinical studies demonstrating improved mitochondrial function, enhanced DNA repair capacity, and mitigation of metabolic dysfunction. Clinical trials, though still nascent, have begun to corroborate these benefits, positioning NAD⁺ precursor administration as a promising avenue for therapeutic intervention in degenerative diseases and metabolic syndromes.

Among the most innovative strategies to modulate NAD⁺ metabolism is the pharmacological targeting of NAMPT. Activation of NAMPT represents a compelling method to elevate intracellular NAD⁺ levels more efficiently than precursor supplementation alone. One such activator, P7C3, originally recognized for its neuroprotective properties, has been shown to enhance NAMPT activity, thereby increasing NAD⁺ levels in human cells subjected to chemotherapeutic stress with doxorubicin. This evidence opens the door for P7C3 and similar compounds to be leveraged in treating age-related neurodegenerative conditions.

Moreover, enhancing NAMPT activity in mesenchymal stem cells (MSCs) through P7C3 treatment has been demonstrated to improve their therapeutic efficacy in alleviating inflammatory disorders. This highlights a broader potential utility of NAMPT activators—not solely in metabolic enhancement but also as adjuvants in regenerative medicine and immunomodulation. Such insights underscore NAD⁺ metabolism’s intersection with inflammation and immune responses, an area ripe for future investigation.

The discovery of SBI-797812, a highly potent small molecule NAMPT activator effective at nanomolar concentrations, further exemplifies the therapeutic promise of targeting the NAD⁺ salvage pathway. SBI-797812 not only boosts NMN production in vitro but also elevates NAD⁺ levels in vivo, indicating translational potential for clinical applications aimed at metabolic health and longevity.

Conversely, NAMPT inhibitors wield therapeutic potential in oncology. Cancer cells often exhibit rewired NAD⁺ metabolism to support their rapid proliferation and survival. Inhibitors such as KPT-9274 have been shown to disrupt lipid metabolism in acute myeloid leukemia cells, specifically reducing stearoyl-CoA desaturase activity, thereby inducing apoptosis. This dual role of NAMPT in both normal physiology and pathology encapsulates the nuanced balance required in targeting this enzyme.

Another promising anti-cancer strategy involves the NAMPT inhibitor FK866, which, when combined with platinum-based chemotherapy, suppresses the emergence of therapy-induced senescence-associated, cancer stem-like cells. This synergy points to the potential of combining metabolic pathway inhibitors with conventional chemotherapeutics to overcome resistance and improve patient outcomes.

Despite these advances, significant questions remain regarding the spatial and temporal regulation of NAD⁺ metabolism. NAD⁺ pools are compartmentalized distinctly within the cytoplasm, mitochondria, and nucleus, each mediating unique biochemical and signaling pathways. Understanding tissue- and organ-specific NAD⁺ dynamics is imperative to develop targeted therapies that maximize efficacy while minimizing off-target effects.

Furthermore, the long-term safety profile of chronic NAD⁺ supplementation requires rigorous assessment. While short-term interventions have demonstrated benefits, the potential for adverse effects or metabolic imbalances over prolonged use remains an open question. These considerations are critical as the field moves toward widespread clinical application.

Intriguing recent studies have also illuminated the role of NAD⁺ metabolism in modulating immune responses and inflammation. Given the centrality of immune dysregulation in numerous diseases—including autoimmune disorders and cancer—this avenue represents a highly promising frontier. Future research focused on the crosstalk between NAD⁺ metabolism and immune pathways could unlock novel therapeutic strategies.

Altogether, the burgeoning field of NAD⁺ metabolism research places NAMPT at its epicenter, highlighting its dualistic capacity to influence energy metabolism and epigenetic regulation. This enzyme’s centrality marks it as a prime target for interventions designed to restore cellular vitality in the face of aging, metabolic challenge, and malignancy.

Looking ahead, the challenge lies in harnessing the complexity of NAD⁺ biology to design precision therapies. This endeavor demands a multidisciplinary approach integrating molecular biology, pharmacology, and clinical science. Advances in high-resolution metabolomics and compartment-specific NAD⁺ measurement techniques will be pivotal to unravel this complexity.

Ultimately, leveraging NAD⁺ metabolism therapeutically holds the promise of reshaping treatment paradigms across a spectrum of diseases. As research continues to decode the intimate relationship between NAD⁺, cellular aging, and metabolic health, the prospect of extending healthspan and combating chronic disease through NAD⁺ modulation becomes increasingly tangible.

This synthesis of biochemical insight and therapeutic innovation heralds a new chapter in medicine—one where the fundamental currency of cellular energy, NAD⁺, becomes a fulcrum for enhancing human health and longevity.

Subject of Research:
Nicotinamide phosphoribosyltransferase (NAMPT) and NAD⁺ metabolism in physiology and pathology.

Article Title:
Nicotinamide phosphoribosyltransferase in NAD⁺ metabolism: physiological and pathophysiological implications.

Article References:
Zhang, W., Ren, H., Chen, W. et al. Nicotinamide phosphoribosyltransferase in NAD⁺ metabolism: physiological and pathophysiological implications. Cell Death Discov. 11, 371 (2025). https://doi.org/10.1038/s41420-025-02672-w

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02672-w